Copyright © 2011 Ingrid Garajová et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. American Cancer Society, Cancer Facts & Figures 2009, American Cancer Society, 2009.
2. M. J. Stamos and Z. Murrell, “Management of early rectal T1 and T2 cancers,” Clinical Cancer Research, vol. 13, no. 22, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. I. Chau, G. Brown, D. Cunningham et al., “Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer,” Journal of Clinical Oncology, vol. 24, no. 4, pp. 668–674, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
4. G. Brown, “Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study,” British Medical Journal, vol. 333, no. 7572, pp. 779–782, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
5. R. Sauer, H. Becker, W. Hohenberger et al., “Preoperative versus postoperative chemoradiotherapy for rectal cancer,” The New England Journal of Medicine, vol. 351, no. 17, pp. 1731–1810, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. J. F. Bosset, G. Calais, L. Mineur et al., “Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results - EORTC 22921,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5620–5627, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
7. J. H. Lee, S. H. Kim, J. G. Kim, H. M. Cho, and B. Y. Shim, “preoperative chemoradiotherapy (CRT) followed by laparoscopic surgery for rectal cancer: predictors of the tumor response and the long-term oncologic outcomes,” International Journal of Radiation Oncology Biology Physics, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
8. N. A. Janjan, C. Crane, B. W. Feig et al., “Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer,” American Journal of Clinical Oncology, vol. 24, no. 2, pp. 107–112, 2001. View at Publisher · View at Google Scholar · View at Scopus
9. J. P. Gérard, Y. Rostom, J. Gal, et al., “Can we increase the chance of sphincter saving surgery in rectal cancer with neoadjuvant treatments: lessons from a systematic review of recent randomized trials,” Critical Reviews in Oncology/Hematology. In press.
10. J. P. Gérard, T. Conroy, F. Bonnetain et al., “Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203,” Journal of Clinical Oncology, vol. 24, no. 28, pp. 4620–4625, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
11. J. F. Bosset, L. Collette, G. Calais et al., “Chemotherapy with preoperative radiotherapy in rectal cancer,” The New England Journal of Medicine, vol. 355, no. 11, pp. 1114–1123, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
12. K. Bujko, M. P. Nowacki, A. Nasierowska-Guttmejer et al., “Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy,” Radiotherapy and Oncology, vol. 72, no. 1, pp. 15–24, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
13. K. Bujko, M. P. Nowacki, A. Nasierowska-Guttmejer, W. Michalski, M. Bebenek, and M. Kryj, “Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer,” British Journal of Surgery, vol. 93, no. 10, pp. 1215–1223, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
14. H. G. Moore, A. E. Gittleman, B. D. Minsky et al., “Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection,” Diseases of the Colon and Rectum, vol. 47, no. 3, pp. 279–286, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
15. Y. Francois, C. J. Nemoz, J. Baulieux et al., “Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial,” Journal of Clinical Oncology, vol. 17, no. 8, pp. 2396–2402, 1999. View at Scopus
16. S. F. Kerr, S. Norton, and R. Glynne-Jones, “Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis,” British Journal of Surgery, vol. 95, no. 12, pp. 1534–1540, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
17. D. Pettersson, B. Cederniark, T. Holm et al., “Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer,” British Journal of Surgery, vol. 97, no. 4, pp. 580–587, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
18. O. Glehen, O. Chapet, M. Adham, J. C. Nemoz, and J. P. Gerard, “Long-term results of the Lyons R90-01 randomized trial of preoperative radiotherapy with delayed surgery and its effect on sphincter-saving surgery in rectal cancer,” British Journal of Surgery, vol. 90, no. 8, pp. 996–998, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
19. V. Valentini and B. Glimelius, “Rectal cancer radiotherapy: towards European consensus,” Acta Oncologica, vol. 49, no. 8, pp. 1206–1216, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
20. M. Mohiuddin, W. F. Regine, W. J. John et al., “Preoperative chemoradiation in fixed distal rectal cancer: dose time factors for pathological complete response,” International Journal of Radiation Oncology Biology Physics, vol. 46, no. 4, pp. 883–888, 2000. View at Publisher · View at Google Scholar · View at Scopus
21. M. S. Roh, G. A. Yothers, M. J. O'Connell, et al., “The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04,” in Proceedings of the 47th ASCO Annual Meeting, 2011, abstract 3503.
22. R. Hofheinz, F. K. Wenz, S. Post, et al., “Capecitabine (Cape) versus 5-fluorouracil (5-FU)–based (neo)adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): long-term results of a randomized, phase III trial,” in Proceedings of the 47th ASCO Annual Meeting, 2011, abstract 3504.
23. J. G. Guillem, D. B. Chessin, A. M. Cohen et al., “Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer,” Annals of Surgery, vol. 241, no. 5, pp. 829–838, 2005. View at Publisher · View at Google Scholar · View at Scopus
24. C. W. Lam, W. T. L. Chen, M. T. Liu et al., “Effect of preoperative concurrent chemoradiotherapy in locally advanced low rectal cancer after radical resection surgery,” International Surgery, vol. 90, no. 1, pp. 53–59, 2005. View at Scopus
25. C. Aschele, C. Pinto, S. Cordio, et al., “Preoperative fluorouracil (FU)-based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: pathologic response analysis of the Studio Terapia Adiuvante Retto (STAR)-01 randomized phase III trial,” in Proceedings of the ASCO Annual Meeting, 2009, abstract CRA4008.
26. J. P. Gérard, D. Azria, S. Gourgou-Bourgade et al., “Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2,” Journal of Clinical Oncology, vol. 28, no. 10, pp. 1638–1644, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
27. M. Mohiuddin, K. Winter, E. Mitchell et al., “Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: radiation therapy oncology group trial 0012,” Journal of Clinical Oncology, vol. 24, no. 4, pp. 650–655, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
28. S. Gollins, A. Sun Myint, B. Haylock, et al., “Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes,” Journal of Clinical Oncology, vol. 29, no. 8, pp. 1042–1049, 2011.
29. S. Wong, K. Winter, N. Meropol, et al., “RTOG 0247: a randomized phase II study of neoadjuvant capecitabine and irinotecan versus capecitabine and oxaliplatin with concurrent radiation therapy for locally advanced rectal cancer,” Journal of Clinical Oncology, vol. 26, abstract 4021, 2008.
30. D. Azria, F. Bibeau, N. Barbier et al., “Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer,” BMC Cancer, vol. 5, article no. 62, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
31. J. Giralt, M. De Las Heras, L. Cerezo et al., “The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis,” Radiotherapy and Oncology, vol. 74, no. 2, pp. 101–108, 2005. View at Publisher · View at Google Scholar · View at Scopus
32. J. Giralt, A. Eraso, M. Armengol et al., “Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 54, no. 5, pp. 1460–1465, 2002. View at Publisher · View at Google Scholar · View at Scopus
33. J. S. Kim, J. M. Kim, S. Li et al., “Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 1, pp. 195–200, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
34. S. Li, J. S. Kim, J. M. Kim et al., “Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation,” International Journal of Radiation Oncology Biology Physics, vol. 65, no. 3, pp. 705–712, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. K. L. G. Spindler, J. N. Nielsen, J. Lindebjerg, I. Brandslund, and A. Jakobsen, “Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region,” International Journal of Radiation Oncology Biology Physics, vol. 66, no. 2, pp. 500–504, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
36. W. Zhang, D. J. Park, B. Lu et al., “Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation,” Clinical Cancer Research, vol. 11, no. 2 I, pp. 600–605, 2005. View at Scopus
37. B. G. Czito, C. G. Willett, J. C. Bendell et al., “Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results,” Journal of Clinical Oncology, vol. 24, no. 4, pp. 656–662, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
38. V. Valentini, A. De Paoli, M. A. Gambacorta et al., “Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a Phase I and II Trial (1839IL/0092),” International Journal of Radiation Oncology Biology Physics, vol. 72, no. 3, pp. 644–649, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
39. C. Rödel, D. Arnold, M. Hipp et al., “Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 70, no. 4, pp. 1081–1086, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
40. C. Bengala, S. Bettelli, F. Bertolini et al., “Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer,” Annals of Oncology, vol. 20, no. 3, pp. 469–474, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
41. S. Hu-Lieskovan, D. Vallbohmer, W. Zhang et al., “EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients,” Clinical Cancer Research, vol. 17, no. 15, pp. 5161–5169, 2011. View at Publisher · View at Google Scholar · View at PubMed
42. K. F. Chin, J. Greenman, E. Gardiner, H. Kumar, K. Topping, and J. Monson, “Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer,” British Journal of Cancer, vol. 83, no. 11, pp. 1425–1431, 2000. View at Scopus
43. I. Hyodo, T. Doi, H. Endo et al., “Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer,” European Journal of Cancer, vol. 34, no. 13, pp. 2041–2045, 1998. View at Publisher · View at Google Scholar · View at Scopus
44. A. Nanashima, M. Ito, I. Sekine et al., “Significance of angiogenic factors in liver metastatic tumors originating from colorectal cancers,” Digestive Diseases and Sciences, vol. 43, no. 12, pp. 2634–2640, 1998. View at Publisher · View at Google Scholar · View at Scopus
45. C. G. Willett, D. G. Duda, E. Di Tomaso et al., “Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study,” Journal of Clinical Oncology, vol. 27, no. 18, pp. 3020–3026, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
46. C. H. Crane, C. Eng, B. W. Feig et al., “Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 3, pp. 824–830, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
47. C. Rödel, D. Arnold, H. Becker et al., “Induction chemotherapy before chemoradiotherapy and surgery for locally advanced rectal cancer - is it time for a randomized phase III trial?” Strahlentherapie und Onkologie, pp. 1–7, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
48. M. S. Roh, L. H. Colangelo, M. J. O'Connell et al., “Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03,” Journal of Clinical Oncology, vol. 27, no. 31, pp. 5124–5130, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
49. C. Rödel, T. Liersch, R. M. Hermann et al., “Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer,” Journal of Clinical Oncology, vol. 25, no. 1, pp. 110–117, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
50. D. Sebag-Montefiore, H. Rutten, and E. Rullier, “Three-year survival results of CORE (Capecitabine, Oxaliplatin, Radiotherapy, and Excision) study after postoperative chemotherapy in patients with locally advanced rectal adenocarcinoma,” in Proceedings of the ASCO GI Meeting, 2009, abstract 447.
51. L. Milas, N. R. Hunter, K. A. Mason, C. G. Milross, Y. Saito, and L. J. Peters, “Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel,” Cancer Research, vol. 55, no. 16, pp. 3564–3568, 1995. View at Scopus
52. A. G. Taghian, R. Abi-Raad, S. I. Assaad et al., “Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 1951–1961, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
53. R. Glynne-Jones, J. Grainger, M. Harrison, P. Ostler, and A. Makris, “Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?” British Journal of Cancer, vol. 94, no. 3, pp. 363–371, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
54. C. Fernández-Martos, C. Pericay, J. Aparicio et al., “Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo Cáncer de Recto 3 study,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 859–865, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
55. Y. J. Chua, Y. Barbachano, D. Cunningham et al., “Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial,” The Lancet Oncology, vol. 11, no. 3, pp. 241–248, 2010. View at Publisher · View at Google Scholar · View at Scopus
56. D. Koeberle, R. Burkhard, R. Von Moos et al., “Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer,” British Journal of Cancer, vol. 98, no. 7, pp. 1204–1209, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
57. F. A. Calvo, F. J. Serrano, J. A. Diaz-González et al., “Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation,” Annals of Oncology, vol. 17, no. 7, pp. 1103–1110, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
58. C. Ortholan, E. Francois, O. Thomas et al., “Role of radiotherapy with surgery for T3 and resectable T4 rectal cancer: evidence from randomized trials,” Diseases of the Colon and Rectum, vol. 49, no. 3, pp. 302–310, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
59. D. W. Kim, D. Y. Kim, T. H. Kim et al., “Is T classification still correlated with lymph node status after preoperative chemoradiotherapy for rectal cancer?” Cancer, vol. 106, no. 8, pp. 1694–1700, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
60. C. Capirci, V. Valentini, L. Cionini et al., “Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal Cancer: long-term analysis of 566 ypCR patients,” International Journal of Radiation Oncology Biology Physics, vol. 72, no. 1, pp. 99–107, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
61. H. M. Quah, J. F. Chou, M. Gonen et al., “Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation,” Cancer, vol. 113, no. 1, pp. 57–64, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
62. C. Rödel, P. Martus, T. Papadoupolos et al., “Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8688–8696, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
63. T. Liersch, C. Langer, B. M. Ghadimi et al., “Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4062–4068, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
64. V. Valentini and B. Glimelius, “Rectal cancer radiotherapy: towards European Consensus,” Acta Oncologica, vol. 49, no. 8, pp. 1206–1216, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
65. “National Comprehensive Cancer Network: National Comprehensive Cancer Network clinical practice guidelines, Rectal cancer,” 2010, http://www.nccn.org/.
66. B. Glimelius, J. Oliveira, and ESMO Guidelines Working Group, “Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up,” Annals of Oncology, vol. 20, supplement 4, pp. 54–56, 2009.
67. V. Valentini, C. Aristei, B. Glimelius et al., “Multidisciplinary rectal cancer management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2),” Radiotherapy and Oncology, vol. 92, no. 2, pp. 148–163, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
68. L. Collette, J. F. Bosset, M. Den Dulk et al., “Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group,” Journal of Clinical Oncology, vol. 25, no. 28, pp. 4379–4386, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
69. Quasar Collaborative Group, R. Gray, J. Barnwell, et al., “Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study,” The Lancet, vol. 370, no. 9604, pp. 2020–2029, 2007.
70. J. W. Huh, “Postoperative adjuvant chemotherapy in patients with ypN+ after preoperative chemoradiation for rectal cancer: need for randomized trials,” Journal of Surgical Oncology. In press. View at Publisher · View at Google Scholar · View at PubMed
71. R. Fietkau, M. Barten, G. Klautke et al., “Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer,” Diseases of the Colon and Rectum, vol. 49, no. 9, pp. 1284–1292, 2006. View at Publisher · View at Google Scholar · View at PubMed
72. A. K. P. Chan, A. Wong, D. Jenken, J. Heine, D. Buie, and D. Johnson, “Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy,” International Journal of Radiation Oncology Biology Physics, vol. 61, no. 3, pp. 665–677, 2005. View at Publisher · View at Google Scholar · View at PubMed
73. K. Bujko, W. Michalski, L. Kepka, et al., “Polish Colorectal Study Group. Association between pathologic response in metastatic lymph nodes after preoperative chemoradiotherapy and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial,” International Journal of Radiation Oncology Biology Physics, vol. 67, no. 2, pp. 369–377, 2007.
74. K. Bujko, R. Glynne-Jones, and M. Bujko, “Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials,” Annals of Oncology, vol. 21, no. 9, pp. 1743–1750, 2010. View at Publisher · View at Google Scholar · View at PubMed
75. J. W. Huh, H. R. Kim, et al., “Postoperative chemotherapy after neoadjuvant chemoradiation and sumery for rectal cancer: is it essentials for patiens with ypT0-2N0?” Journal of Surgical Oncology, vol. 100, pp. 387–391, 2009.
76. P. Das, J. M. Skibber, M. A. Rodriguez-Bigas et al., “Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer,” American Journal of Clinical Oncology, vol. 29, no. 3, pp. 219–224, 2006. View at Publisher · View at Google Scholar · View at PubMed
77. L. Collette and J. F. Bosset, “Adjuvant chemotherapy following neoadjuvant therapy of rectal cancer. The type of neoadjuvant therapy (chemoradiotherapy or radiotherapy) may be important for selection of patients,” Journal of Clinical Oncology, vol. 26, pp. 508–509, 2007.
78. N. B. Merchant, J. G. Guillem, P. B. Paty et al., “T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy,” Journal of Gastrointestinal Surgery, vol. 3, no. 6, pp. 642–647, 1999.
79. A. I. Picon, H. G. Moore, S. S. Sternberg et al., “Prognostic significance of depth of gross or microscopic perirectal fat invasion in T3 N0 M0 rectal cancers following sharp mesorectal excision and no adjuvant therapy,” International Journal of Colorectal Disease, vol. 18, no. 6, pp. 487–492, 2003. View at Publisher · View at Google Scholar · View at PubMed
80. C. G. Willett, K. Badizadegan, M. Ancukiewicz, and P. C. Shellito, “Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy?” Diseases of the Colon and Rectum, vol. 42, no. 2, pp. 167–173, 1999. View at Publisher · View at Google Scholar
81. L. L. Gunderson, D. J. Sargent, J. E. Tepper et al., “Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis,” International Journal of Radiation Oncology Biology Physics, vol. 54, no. 2, pp. 386–396, 2002. View at Publisher · View at Google Scholar
82. L. L. Gunderson, D. J. Sargent, J. E. Tepper et al., “Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis,” Journal of Clinical Oncology, vol. 22, no. 10, pp. 1785–1796, 2004. View at Publisher · View at Google Scholar · View at PubMed
83. J. G. Guillem, J. A. Díaz-González, B. D. Minsky et al., “cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted,” Journal of Clinical Oncology, vol. 26, no. 3, pp. 368–373, 2008. View at Publisher · View at Google Scholar · View at PubMed
84. R. Lombardi, D. Cuicchi, C. Pinto et al., “Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment?” Annals of Surgical Oncology, vol. 17, no. 3, pp. 838–845, 2010. View at Publisher · View at Google Scholar · View at PubMed
85. S. Bipat, A. S. Glas, F. J. M. Slors, A. H. Zwinderman, P. M. M. Bossuyt, and J. Stoker, “Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-a meta-analysis,” Radiology, vol. 232, no. 3, pp. 773–783, 2004. View at Publisher · View at Google Scholar · View at PubMed
86. N. N. Baxter, A. M. Morris, D. A. Rothenberger, and J. E. Tepper, “Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis,” International Journal of Radiation Oncology Biology Physics, vol. 61, no. 2, pp. 426–431, 2005. View at Publisher · View at Google Scholar · View at PubMed
87. M. W. Wichmann, C. Müller, G. Meyer et al., “Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer,” Archives of Surgery, vol. 137, no. 2, pp. 206–210, 2002.
88. D. M. Schaffzin and W. D. Wong, “Endorectal ultrasound in the preoperative evaluation of rectal cancer,” Clinical Colorectal Cancer, vol. 4, no. 2, pp. 124–132, 2004.
89. J. Zhu, Y. Xu, W. Gu et al., “Adjuvant therapy for T3N0 rectal cancer in the total mesorectal excision era- identification of the high risk patients,” Radiation Oncology, vol. 5, no. 1, article no. 118, 2010. View at Publisher · View at Google Scholar · View at PubMed
90. M. Mohiuddin, J. Marks, and G. Marks, “Management of rectal cancer: short- vs.long-course preoperative radiation,” International Journal of Radiation Oncology Biology Physics, vol. 72, no. 3, pp. 636–643, 2008. View at Publisher · View at Google Scholar · View at PubMed
91. C. A. M. Marijnen, K. C. M. J. Peeters, H. Putter, et al., “Long term results, toxicity, and quality of life in the TME trial,” Radiotherapy and Oncology, vol. 73, p. 127, 2004.
92. K. C. M. J. Peeters, C. J. H. Van De Velde, J. W. H. Leer et al., “Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients-a Dutch Colorectal Cancer Group Study,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 6199–6206, 2005. View at Publisher · View at Google Scholar · View at PubMed
93. H. Birgisson, L. Påhlman, U. Gunnarsson, and B. Glimelius, “Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8697–8705, 2005. View at Publisher · View at Google Scholar · View at PubMed
94. H. Birgisson, L. Påhlman, U. Gunnarsson, and B. Glimelius, “Occurrence of second cancers in patients treated with radiotherapy for rectal cancer,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 6126–6131, 2005. View at Publisher · View at Google Scholar · View at PubMed
95. P. Van Duijvendijk, J. F. M. Slors, C. W. Taat et al., “Prospective evaluation of anorectal function after total mesorectal excision for rectal carcinoma with or without preoperative radiotherapy,” American Journal of Gastroenterology, vol. 97, no. 9, pp. 2282–2289, 2002. View at Publisher · View at Google Scholar
96. J. G. Letschert, J. V. Lebesque, B. M. Aleman, et al., “The volume effect in radiation-related late small bowel complications: results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma,” Radiotherapy and Oncology, vol. 32, pp. 116–123, 1994.
97. L. R. Coia, R. J. Myerson, J. E. Tepper, et al., “Late effects of radiation therapy on the gastrointestinal tract,” International Journal of Radiation Oncology Biology Physics, vol. 31, pp. 1213–1236, 1995.
98. J. H. Vironen, M. Kairaluoma, A. M. Aalto, and I. H. Kellokumpu, “Impact of functional results on quality of life after rectal cancer surgery,” Diseases of the Colon and Rectum, vol. 49, no. 5, pp. 568–578, 2006. View at Publisher · View at Google Scholar · View at PubMed
99. A. Nesbakken, K. Nygaard, T. Bull-Njaa, E. Carlsen, and L. M. Eri, “Bladder and sexual dysfunction after mesorectal excision for rectal cancer,” British Journal of Surgery, vol. 87, no. 2, pp. 206–210, 2000. View at Publisher · View at Google Scholar · View at PubMed
100. O. Dahl, A. Horn, I. Morild et al., “Low-dose preoperative radiation postpones recurrences in operable rectal cancer. Results of a randomized multicenter trial in Western Norway,” Cancer, vol. 66, no. 11, pp. 2286–2294, 1990. View at Publisher · View at Google Scholar
101. G. J. Frykholm, B. Glimelius, and L. Pahlman, “Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results of a randomized trial and an evaluation of late secondary effects,” Diseases of the Colon and Rectum, vol. 36, no. 6, pp. 564–572, 1993.
102. C. A. M. Marijnen, C. J. H. Van De Velde, H. Putter et al., “Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 1847–1858, 2005. View at Publisher · View at Google Scholar · View at PubMed
103. S. Pucciarelli, P. Del Bianco, F. Efficace et al., “Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study,” Annals of Surgery, 2010. View at Publisher · View at Google Scholar · View at PubMed
104. P. Quirke, M. F. Dixon, P. Durdey, and N. S. Williams, “Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision,” Lancet, vol. 2, no. 8514, pp. 996–999, 1986.
105. J. A. Wilks, C. Liebig, S. H. Tasleem et al., “Rectal cancer patients benefit from implementation of a dedicated colorectal cancer center in a Veterans affairs medical center,” American Journal of Surgery, vol. 198, no. 1, pp. 100–104, 2009. View at Publisher · View at Google Scholar · View at PubMed
106. Y. W. Kim, N. K. Kim, B. S. Min et al., “Factors associated with anastomotic recurrence after total mesorectal excision in rectal cancer patients,” Journal of Surgical Oncology, vol. 99, no. 1, pp. 58–64, 2009. View at Publisher · View at Google Scholar · View at PubMed
107. R. J. Heald, B. J. Moran, R. D. H. Ryall, R. Sexton, and J. K. MacFarlane, “Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997,” Archives of Surgery, vol. 133, no. 8, pp. 894–899, 1998. View at Publisher · View at Google Scholar
108. H. Ogiwara, T. Nakamura, and S. Baba, “Variables related to risk of recurrence in rectal cancer without lymph node metastasis,” Annals of Surgical Oncology, vol. 1, no. 2, pp. 99–104, 1994. View at Publisher · View at Google Scholar
109. O. F. Dent, N. Haboubi, P. H. Chapuis et al., “Assessing the evidence for an association between circumferential tumour clearance and local recurrence after resection of rectal cancer,” Colorectal Disease, vol. 9, no. 2, pp. 112–121, 2007. View at Publisher · View at Google Scholar · View at PubMed
110. K. F. Birbeck, C. P. Macklin, N. J. Tiffin et al., “Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery,” Annals of Surgery, vol. 235, no. 4, pp. 449–457, 2002. View at Publisher · View at Google Scholar
111. I. D. Nagtegaal, C. A. M. Marijnen, E. K. Kranenbarg, C. J. H. Van De Velde, and J. H. J. M. Van Krieken, “Circumferential margin involvement is still an important predictor of local recurrence in rectal carcinoma: not one millimeter but two millimeters is the limit,” American Journal of Surgical Pathology, vol. 26, no. 3, pp. 350–357, 2002. View at Publisher · View at Google Scholar
112. H. G. Moore, E. Riedel, B. D. Minsky et al., “Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy,” Annals of Surgical Oncology, vol. 10, no. 1, pp. 80–85, 2003.
113. H. S. Tilney, P. P. Tekkis, P. S. Sains, V. A. Constantinides, and A. G. Heriot, “Factors affecting circumferential resection margin involvement after rectal cancer excision,” Diseases of the Colon and Rectum, vol. 50, no. 1, pp. 29–36, 2007. View at Publisher · View at Google Scholar · View at PubMed
114. T. Leibold, J. Shia, L. Ruo et al., “Prognostic implications of the distribution of lymph node metastases in rectal cancer after neoadjuvant chemoradiotherapy,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2106–2111, 2008. View at Publisher · View at Google Scholar · View at PubMed
115. G. Theodoropoulos, W. E. Wise, A. Padmanabhan et al., “T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival,” Diseases of the Colon and Rectum, vol. 45, no. 7, pp. 895–903, 2002. View at Publisher · View at Google Scholar
116. I. Garajová, O. Slabý, M. Svoboda et al., “Gene expression profiling in prediction of tumor response to neoadjuvant concomitant chemoradiotherapy in patients with locally advanced rectal carcinoma: pilot study,” Casopis Lekaru Ceskych, vol. 147, no. 7, pp. 381–386, 2008.